Investigational drug · Phase 2
EVER001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EVER001"
First trial start
2026
May 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EVER001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Minimal Change Disease (MCD)
- IgA Nephropathy (IgAN)
- Focal Segmental Glomerulosclerosis (FSGS)
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "EVER001" as an intervention, largest first.
Everest Medicines (China) Co.,Ltd.Industry
NCT07614477 · 45 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2028
Drug: EVER001 · For: Minimal Change Disease (MCD); IgA Nephropathy (IgAN); Focal Segmental Glomerulosclerosis (FSGS)
Sites: Beijing, China; Tianjin, China
Everest Medicines (China) Co.,Ltd.Industry
NCT05800873 · 31 participants · Start May 15, 2023 · Primary completion Jul 27, 2026
Drug: EVER001; EVER001 · For: Primary Membranous Nephropathy
Sites: Changsha, China; Chongqing, China; Guangzhou, China · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Minimal Change Disease (MCD)
- BAT4406FPhase 32 trials
Bio-Thera Solutions · Optic Neuromyelitis Spectrum Disease, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.